Nexalin Technology (NASDAQ:NXL – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.
Earnings & Valuation
This table compares Nexalin Technology and IceCure Medical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexalin Technology | $300,000.00 | 6.42 | -$8.22 million | ($14.41) | -0.18 |
| IceCure Medical | $3.38 million | 1.12 | -$15.06 million | ($8.52) | -0.13 |
Profitability
This table compares Nexalin Technology and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexalin Technology | -4,141.94% | -278.24% | -218.42% |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
Insider & Institutional Ownership
0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and recommmendations for Nexalin Technology and IceCure Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
| IceCure Medical | 2 | 0 | 2 | 0 | 2.00 |
IceCure Medical has a consensus target price of $30.00, suggesting a potential upside of 2,627.27%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than Nexalin Technology.
Risk & Volatility
Nexalin Technology has a beta of 4.08, meaning that its share price is 308% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.
Summary
IceCure Medical beats Nexalin Technology on 8 of the 13 factors compared between the two stocks.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
